Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

Abstract

We estimated the age‐specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (APOE) genotype, and cerebrospinal fluid tau on disease duration.

Document Details

Document Type
Pub Defense Publication
Publication Date
Jun 01, 2019
Source ID
10.1016/j.jalz.2019.04.001

Entities

People

  • Aibl Research Group
  • Ardo Van Den Hout
  • For The Alzheimer Disease Neuroimaging Initiative
  • Frans R.j. Verhey
  • Graciela Muniz‐terrera
  • Henrik Zetterberg
  • Hilkka Soininen
  • Ictus/dsa Study Groups
  • Ingmar Skoog
  • Isabelle Bos
  • Kaj Blennow
  • Lisa Vermunt
  • Luisa Spiru
  • Magda Tsolaki
  • Marcel Olde Rikkert
  • Paul Maruff
  • Philip Scheltens
  • Pierre‐jean Ousset
  • Pieter Jelle Visser
  • Ron Handels
  • Sietske A.m. Sikkes
  • Silke Kern
  • Wiesje M. Van Der Flier
  • Yvonne Freund‐levi
  • Åsa K. Wallin

Organizations

  • Alzheimer's Association
  • Aristotle University of Thessaloniki
  • COGSTATE LTD
  • Carol Davila University of Medicine and Pharmacy
  • Centre Hospitalier Universitaire Toulouse
  • European Commission
  • Harvard Medical School
  • Interreg
  • Karolinska University Hospital
  • King's College London
  • Lund University
  • Maastricht University
  • National Institutes of Health
  • Radboud University Medical Centre
  • Sahlgrenska University Hospital
  • Seventh Framework Programme
  • Swedish Research Council
  • Swedish Research Council for Health Working Life and Welfare
  • United States Department of Defense
  • University College London
  • University Medical Center Utrecht
  • University of Eastern Finland
  • University of Edinburgh
  • Vrije Universiteit Amsterdam

Tags

Fields of Study

  • Biology
  • Medicine
  • Psychology

Readers

  • Gender and Food Studies
  • Traumatic Brain Injury (TBI) and Cognitive Aging in the Guam and Border Populations Affected by Alzheimer's Disease and Tau-Associated Dementias.